EMA Application withdrawn: Docetaxel SUN — Sun Pharmaceutical Industries Europe B.V.

View source ↗

Summary

The EMA withdrew the application for Docetaxel SUN by Sun Pharmaceutical Industries Europe B.V. for multiple cancer indications.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Neoplasms
• Carcinoma Non-small-cell Lung
• Gastrointestinal Neoplasms
• Head and Neck Neoplasms
• Prostatic Neoplasms

Drugs mentioned

• Docetaxel SUN (docetaxel)

Snippet

Status: Application withdrawn. Therapeutic area: Prostatic Neoplasms;Carcinoma, Non-Small-Cell Lung;Gastrointestinal Neoplasms;Breast Neoplasms;Head and Neck Neoplasms. MAH: Sun Pharmaceutical Industries Europe B.V.. Decision date: 24/06/2016